A warm welcome to Jens Holmberg, PhD, the latest addition to our team. Jens has a background in preclinical inflammation research with extensive experience in inflammatory in vivo and in vitro models. During his 15 years of post-PhD-experience at Biotech & Medtech companies, Jens has also experienced chief officer positions with focus on putting the company in a scientifically competitive position and to build company value. Jens will in his position as Scientific Director support our CRO team and also function as the project leader for Redoxis work in the Neutrocure program (H2020-FETOPEN) funded by the European union. We are very happy to have Jens aboard and are looking forward to some great research during the next years.
We are continuously adding more assays and models to our portfolio while also actively improving our current models. In collaboration with Cellevate AB we have further developed our ex vivo models of inflammation. Cellevate is an innovative biotech company using nanomaterials to develop the next generation 3D cell culture systems. By using Cellevates 3D cell culture scaffolds we have gained increased stability and predictability in our immune cell stimulation assays (murine and human). These models provide a versatile tool for basic understanding and evaluation of effects on immune cell activation and can be used for tailored studies on project specific subsets, targets or biomarkers. Traditionally, in vitro models have suffered from major limitations in predictability due to altererd morphology of cells during culture. By mimicking the structures in which cells resides in vivo during evaluation of potential new therapies the likelihood of selecting biologically relevant substances for in vivo experiments can be increased.
We are now providing our assays for immune cell activation ex vivo with 3D cell culture setup. Contact us at firstname.lastname@example.org for more information on how we can tailor these models to suit your specific project. For more information on Cellevates 3D cell culture stystems contact email@example.com.
Redoxis AB has signed an agreement with Taconic Biosciences, Inc for service of characterization of cellular composition of Taconic’s humanized immune system mice. This contract covers a recurrent service spanning over three years.
“We are very excited about the collaboration with Taconic, which will beneficially impact Redoxis by adding value and financial stability to our in vitro service platform” says Malin Hultqvist Hopkins, CEO, Redoxis.
For additional information please contact:
As of beginning of March, Redoxis is now a registered trademark in the US. Redoxis has previously been a registered trademark in Sweden and European Union and was lately approved for registration by the United States Patent and Trademark Office.
“The registration of the trademark Redoxis in the US is an important step of our internationalisation strategy to increase Redoxis recognition within the American market for CRO services” says Peter Olofsson, founder and board member of Redoxis.
The current Covid-19 situation is clearly affecting all of us but Redoxis CRO services are still fully operational. In addition to our already validated and standardized animal models we routinely implement and set up new models on demand. With a fully equipped lab, we can also set up in vitro assays on demand, including flow cytometry, ELISA, Luminex and qPCR.
Contact us for a discussion on who we can facilitate and assist your preclinical development in inflammation and autoimmunity.